Recon: GSK, Alector in $2.2B deal for Parkinson’s, Alzheimer’s drugs; Merck to withdraw accelerated approval for Keytruda in 3rd-line gastric cancer
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesPharmaceuticalsRegulatory Intelligence/Policy